The same event can reach both: a study opening is one line under its program in the brief, and one study’s change in the alerts.
The registry lists 2,273 studies for Myocardial Infarction across more than 10 countries. 373 are recruiting or about to start. 1,217 of them are mainly about Myocardial Infarction (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-18. Counting its 5 narrower conditions too, such as ST Elevation Myocardial Infarction: 3,337 studies, 675 open.
ClinicalTrials.gov finds 3,922 studies for Myocardial Infarction.How that becomes 2,274 hereChecked on ClinicalTrials.gov . The studies here are updated every night.
This page counts the studies the registry files under Myocardial Infarction, and those it files under no condition that list Myocardial Infarctionthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. Only this comparison waits for its turn: it is asked again about once a week, so between two checks the registry's number can run a little ahead of it. How condition pages count
3,922Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
−275List Myocardial Infarction as a condition, but the registry did not file them under itMost often written as “Acute Myocardial Infarction” (184), “Acute Myocardial Infarction (AMI)” (23), and “Coronary Artery Disease With Myocardial Infarction” (8). The registry filed them under other conditions only, most often Acute Coronary Syndrome (47) and Coronary Artery Disease (38).
−315Match it another way245 name it in the title, 46 in a keyword, and 24 by a synonym or other text the search reads.
2,274The count on this page305 of them list Myocardial Infarction in their own words; the registry filed them under no condition.
Every program with a company-led study here in the last two years, whatever its size: 13 programs from 12 companies, 5 with this as their studies’ main aim; 4 with a live phase 3 study; 4 primary completions in the next 12 months. Compare Novartis, Amgen and AO GENERIUM here →
Comparator & background therapies
What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.
“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.
The 2 in phase 3 with the nearest primary completion, of 13 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.
Primary completion in the next 12 months (4)
Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.
29 Jan 2027 est.ziltivekimab· Novo Nordisk A/S · Phase 3main aimNCT06118281 ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack — primary endpoint: Time to first occurrence of a 3-component major adverse cardiovascular event (MACE) endpoint comprising: Cardiovascular (CV) death, Non-fatal myocardial infarction (MI), Non-fatal stroke · 10,000 enrolled
8 Feb 2027 est.orticumab· Abcentra · Phase 2named, not the main aimNCT06927739 Focused Orticumab Research for Treating Inflammation in Coronary Arteries — primary endpoint: Percent change from baseline of the mean Fat Attenuation Index (FAI) score for the 3 coronary arteries (RCA, LAD and LCX) for orticumab compared to placebo at 24 weeks · 240 enrolled
30 Jun 2027 est.Xolatryp· Nyrada Pty Ltd · Phase 2named, not the main aimNCT07362446 Prevention of Reperfusion Injury Outcomes Through Effective Cardioprotection Targeting Myocardial Infarction — primary endpoint: Incidence of Adverse Events · 300 enrolled
Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.
What is being tested here
Drugs under test in Myocardial Infarction studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
118studies finish main data collection within a year7 of them phase 3
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger. 17 (7%) take children under 18. 2 (1%) are for women only and 0 (0%) for men only; 27 (11%) take healthy volunteers.
Across all 2,273 studies, recruiting or not: 14% stop at 75 or younger and 4% at 65; 10% take children; 1% are for women only and 3% for men only; 9% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Myocardial Infarction studies take
Of 87 phase 4 interventional studies under Myocardial Infarction, half reached primary completion within 42 months of starting, counting those still running.
Start to primary completion
Every sponsor
Industry
Non-industry
Phase 1
26 mo8–40 · 13 studies
—
—
Phase 2
27 mo19–42 · 45 studies
—
—
Phase 3
44 mo30–77 · 58 studies
—
41 mo24–73 · 34 studies
Phase 4
42 mo22–78 · 87 studies
—
45 mo22–78 · 83 studies
Interventional, no phase
34 mo15–57 · 355 studies
31 mo15–49 · 33 studies
36 mo14–58 · 322 studies
Observational
48 mo18–114 · 335 studies
17 mo7–32 · 37 studies
55 mo21–140 · 298 studies
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 20, 2026.